Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer

Keyphrases

• Prostate Cancer 100%
• Hybrid Radio 100%
• Preclinical Evaluation 100%
• Lutetium-177 (177Lu) 100%
• Prostate-specific Antigen 100%
• Synthetic Evaluation 100%
• Endoradiotherapy 100%
• Apparent Molecular Weight 23%
• Pharmacokinetics 11%
• Biodistribution Studies 11%
• LNCaP Cells 11%
• Kidney 5%
• Clinical Investigation 5%
• Tumor 5%
• Application-oriented 5%
• Systematic Comparison 5%
• Blood Pool 5%
• SPECT Imaging 5%
• Prostate Cancer Patients 5%
• Human Serum Albumin 5%
• Dosimetry 5%
• Targeting Ligands 5%
• Cell Measurement 5%
• Diagnostic Applications 5%
• After Injection 5%
• Tumor-bearing Mice 5%
• Tumor Accumulation 5%
• Non-target 5%
• Internalization Efficiency 5%
• Tumor Uptake 5%
• Kidney Uptake 5%
• Gallium(III) 5%
• Absorbed Dose 5%
• Human Serum Albumin Binding 5%
• Radioligand Therapy 5%
• LNCaP 5%
• Half Maximal Inhibitory Concentration 5%
• Small Animal SPECT 5%
• 177Lu Labeling 5%
• Kidney Accumulation 5%
• Lipophilicity Determination 5%
• Human Serum Albumin Interaction 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Prostate Specific Membrane Antigen 100%
• Lutetium 177 100%
• Neoplasm 22%
• Human Serum Albumin 16%
• Mouse 11%
• Pharmacokinetics 11%
• Biodistribution 11%
• Lipophilicity 5%
• Dosimetry 5%
• Lead Compound 5%
• Tracer 5%
• Radioligand 5%
• IC50 5%